Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:author |
gptkb:Mark_A._Socinski
|
| gptkbp:endPoint |
overall survival
progression-free survival |
| gptkbp:enrollment |
1202
|
| https://www.w3.org/2000/01/rdf-schema#label |
IMpower150
|
| gptkbp:includes |
no EGFR or ALK genomic tumor aberrations
|
| gptkbp:location |
multinational
|
| gptkbp:number |
gptkb:NCT02366143
|
| gptkbp:period |
Phase 3
|
| gptkbp:population |
patients with metastatic non-squamous non-small cell lung cancer
|
| gptkbp:publicationYear |
2018
|
| gptkbp:publishedIn |
gptkb:New_England_Journal_of_Medicine
|
| gptkbp:result |
improved overall survival with atezolizumab combination
|
| gptkbp:sponsor |
gptkb:Genentech
|
| gptkbp:startYear |
2016
|
| gptkbp:studiedCancerType |
gptkb:non-small_cell_lung_cancer
|
| gptkbp:studiedDrug |
gptkb:bevacizumab
gptkb:atezolizumab gptkb:carboplatin paclitaxel |
| gptkbp:bfsParent |
gptkb:Non-Small_Cell_Lung_Cancer
|
| gptkbp:bfsLayer |
6
|